Traws Pharma, Inc.(US:TRAW)2025-11-13 12:01Financial Performance - Revenue for the quarter ended September 30, 2025, was zero, compared to $57 thousand for the same period in 2024, reflecting a decline in sales activity[10] - The net loss for the quarter was $4.0 million, or a net loss of $0.34 per share, compared to a net loss of $8.5 million, or $1.49 per share, for the same quarter in 2024, showing an improvement in loss[12] - Total revenue for the nine months ended September 30, 2025, was $2,790,000, compared to $170,000 for the same period in 2024, representing a significant increase[27] - The net loss for the nine months ended September 30, 2025, was $16,613,000, compared to a net loss of $136,601,000 for the same period in 2024, indicating improved financial performance[27] - The company reported a loss from operations of $4,055,000 for the three months ended September 30, 2025, compared to a loss of $8,536,000 for the same period in 2024[27] - The net loss per share of common stock, basic, was $(0.34) for the three months ended September 30, 2025, compared to $(1.49) for the same period in 2024[27] Cash and Liquidity - Cash and cash equivalents as of September 30, 2025, were approximately $6.4 million, down from $21.3 million as of December 31, 2024, indicating a significant decrease in liquidity[7] - Cash and cash equivalents decreased to $6,420,000 as of September 30, 2025, from $21,338,000 as of December 31, 2024[25] - Total current liabilities decreased to $7,887,000 as of September 30, 2025, from $11,533,000 as of December 31, 2024[25] Research and Development - Research and development (R&D) expenses for the quarter totaled $2.3 million, down from $5.1 million in the comparable period in 2024, a decrease of approximately 55%[10] - Research and development expenses for the nine months ended September 30, 2025, were $7,108,000, down from $10,989,000 in the same period of 2024[27] Operating Expenses - General and administrative (G&A) expenses for the quarter were $1.7 million, compared to $3.5 million in the same period in 2024, a reduction of about 49%[11] - Operating expenses for the nine months ended September 30, 2025, totaled $13,297,000, a decrease from $137,266,000 in the same period of 2024[27] Assets and Deficits - The total assets as of September 30, 2025, were $12,443,000, a decrease from $24,962,000 as of December 31, 2024[25] - The company had an accumulated deficit of $(632,541,000) as of September 30, 2025, compared to $(649,154,000) as of December 31, 2024[25] Product Development and Market Opportunities - Ratutrelvir is expected to provide topline data by year-end 2025 from Phase 2 studies, with prior Phase 1 studies showing plasma drug levels maintained four times above the EC90 over a 10-day treatment period[4] - The U.S. market opportunity for Ratutrelvir is estimated to be multi-billion dollars, targeting treatment for acute COVID infection and Long COVID[4] - Tivoxavir Marboxil (TXM) is positioned as a potential best-in-class single-dose treatment for bird flu and seasonal flu, with a similar multi-billion dollar market opportunity[3] - Traws Pharma acquired significant intellectual property and assets for $2.6 million, enhancing its antiviral portfolio[8] - The overall response rate for rigosertib in treating recessive dystrophic epidermolysis bullosa associated squamous cell carcinoma was reported at 80%, with complete responses in 50% of evaluable patients[9]